JP Morgan Chase
ACHV icon

JP Morgan Chase’s Achieve Life Sciences ACHV Stock Holding History

JP Morgan Chase’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
32,289
+32,270
+169,842% +$154K ﹤0.01% 5619
2026
Q1 		$51 Hold
19
– – ﹤0.01% 7358
2025
Q4 		$94 Hold
19
– – ﹤0.01% 7217
2025
Q3 		$60 Sell
19
-2,241
-99% -$6.15K ﹤0.01% 7209
2025
Q2 		$5.11K Sell
2,260
-26,003
-92% -$74.1K ﹤0.01% 6414
2025
Q1 		$75.5K Sell
28,263
-31,002
-52% -$96.4K ﹤0.01% 5705
2024
Q4 		$209K Buy
59,265
+44,311
+296% +$201K ﹤0.01% 5456
2024
Q3 		$70.9K Buy
14,954
+277
+2% +$1.26K ﹤0.01% 5849
2024
Q2 		$69K Buy
+14,677
New +$70.7K ﹤0.01% 5718
2023
Q2 		– Sell
-250
Closed -$1.7K – 6870
2023
Q1 		$1.7K Buy
+250
New +$1.19K ﹤0.01% 6469
2019
Q3 		– Sell
-60
Closed -$2K – 5685
2019
Q2 		$2K Buy
+60
New +$4.24K ﹤0.01% 5681
2016
Q4 		– Hold
0
– – – 4985
2016
Q3 		– Hold
0
– – – 4508
2016
Q2 		– Hold
0
– – – 4745

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JP Morgan Chase's ACHV Position: Q2 2026 in Review

JP Morgan Chase increased its Achieve Life Sciences (ACHV) stake by 169,842% in Q2 2026, buying an estimated $154K and bringing the position to 32,289 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #5619.

JP Morgan Chase first reported a position in ACHV in Q2 2019 and has held it in 11 quarters since. The position peaked at $209K in Q4 2024. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • JP Morgan Chase held 32,289 shares of Achieve Life Sciences worth $201K as of Q2 2026.
  • JP Morgan Chase bought 32,270 Achieve Life Sciences shares in Q2 2026, an estimated $154K.
  • Achieve Life Sciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5619 holding.
  • JP Morgan Chase first reported a position in Achieve Life Sciences in Q2 2019 and has held it in 11 quarters since.
  • JP Morgan Chase's Achieve Life Sciences position peaked at $209K in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.